Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Erişim
info:eu-repo/semantics/closedAccessTarih
2022Yazar
Gürbüz, MustafaKutlu, Yasin
Akkuş, Erman
Köksoy, Elif Berna
Köse, Naziyet
Öven, Bala Başak
Oyan Uluç, Başak
Demiray, Atike Gökçen
Erdem, Dilek
Demir, Bilgin
Turhal, Nazım Serdar
Üskent, Necdet
Akbaş, Sinem
Selçukbiricik, Fatih
İnal, Ali
Bilici, Ahmet
Ölmez, Ömer Fatih
Çabuk, Devrim
Ünal, Çağlar
Hizal, Mutlu
Şendur, Mehmet Ali Nahit
Korkmaz, Mustafa
Karadurmuş, Nuri
Ertürk, İsmail
Göksu, Sema Sezgin
Tatlı, Ali Murat
Güven, Deniz Can
Kılıçkap, Saadettin
Paksoy, Nail
Aydıner, Adnan
Yeşil Çınkır, Havva
Özkul, Özlem
Öztürk, Akın
Ballı, Sevinç
Kemal, Yasemin
Erdoğan, Atike Pınar
Er, Özlem
Yumuk, Perran Fulden
Demirkazık, Ahmet
Üst veri
Tüm öğe kaydını gösterKünye
Gürbüz, M., Kutlu, Y., Akkuş, E., Köksoy, E. B., Köse, N., Öven, B. B. ... Demirkazık, A. (2022). Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group. Journal of Cancer Research and Clinical Oncology, 148(12), 3547-3555. https://doi.org/10.1007/s00432-022-04087-xÖzet
Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.
WoS Q Kategorisi
Q2Scopus Q Kategorisi
Q1Kaynak
Journal of Cancer Research and Clinical OncologyCilt
148Sayı
12Koleksiyonlar
- Makale Koleksiyonu [3642]
- PubMed İndeksli Yayınlar Koleksiyonu [4039]
- Scopus İndeksli Yayınlar Koleksiyonu [6273]
- WoS İndeksli Yayınlar Koleksiyonu [6417]